Inhibition of cyclooxygenase-2: An approach to preventing cancer of the upper aerodigestive tract

Annals of the New York Academy of Sciences

Volumn 952, Issue , 2001, Pages 109-115

  Dannenberg, Andrew J ^a,c,d   Altorki, Nasser K ^a,c   Boyle, Jay O ^b,c   Lin, Derrick T ^b   Subbaramaiah, Kotha ^a,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c STRANG CANCER PREVENTION CENTER   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Aerodigestive; Chemoprevention; Cyclooxygenase 2; Nonsteroidal anti inflammatory drugs; Prostaglandins

Indexed keywords

CARBOXYLYASE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN SYNTHASE; SULINDAC;

CANCER PREVENTION; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REGULATORY MECHANISM;

EID: 0035683884     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2001.tb02731.x     Document Type: Conference Paper

References (52)

1. 2 in human colon cancer cells
2. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
3. 2 inhibits TNF-alpha release via a mechanism involving IL-10
4. Prostaglandins in squamous cell carcinoma of the head and neck: A preliminary study
5. Prostaglandins and human lung carcinomas
6. Aspirin use and reduced risk of fatal colon cancer
7. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development
8. Cyclooxygenase-2 over-expression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
9. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment
10. Prostaglandin synthase 2
11. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells
12. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
13. Expression of cyclooxygenase-2 in human gastric carcinoma
14. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas
15. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
16. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck
17. Expression of cyclooxygenase-2 in human lung carcinoma
18. Cyclooxygenase-2 is overexpressed in human cervical cancer
19. Dihydroxy bile acids activate the transcription of cyclooxygenase-2
20. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells
21. Inhibition of cyclooxygenase-2 gene expression by p53
22. Over-expression of cyclooxygenase (Cox)-2 is sufficient to induce tumorigenesis in transgenic mice
23. Δ716 knockout mice by inhibition of cyclooxygenase-2 (Cox-2)
24. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
25. Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor
26. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor
27. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis
28. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398
29. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats
30. Increased expression of cyclooxygenase-2 protein and 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide
31. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells
32. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
33. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice
34. Specific inhibition of cyclooxygenase-2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis
35. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model
36. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo
37. Prostaglandin H synthase and xenobiotic oxidation
38. Carcinogen substrate specificity of human COX-1 and COX-2
39. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis
40. Host cyclooxygenase-2 modulates carcinoma growth
41. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
42. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2
43. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients
44. Subversion of immune system by tumor cells and role of prostaglandins
45. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
46. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis
47. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
48. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
49. 13-cis-retinoic acid in the treatment of oral leukoplakia
50. Enhanced antitumor activity by co-administration of celecoxib and the chemotherapeutic agents cyclophosphamide and 5-FU
51. Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme
52. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor